Serotonergic Mechanisms in Levodopa-Induced “On-Off” and Sleep Disorders in Parkinson's Disease

References

• Azmitia E. C. The serotonin-producing neurons of the midbrain median and dorsal raphe nuclei. Handbook of psychopharmacology, L. L. Iversen, S. D. Iversen, S. H. Snyder. Plenum, New York 1978; Vol. 9: 233–314
   Google Scholar
• Beasley B. L., Nutt J. G., Davenport R., Chase T. Treatment with tryptophan of levodopa associated psychiatric disturbances. Archives of Neurology 1980; 37: 155–156
   PubMedGoogle Scholar
• Birkmayer W., Riederer P. Die Parkinson-Krankheit: Biochemie, Klinik, Therapie. Springer, New York 1980
   Google Scholar
• Birkmayer W., Danielczyk W., Neumayer E. Nucleus ruber and L-dopa psychosis: Biochemical post-mortem findings. Journal of Neural Transmission 1974; 35: 93–116
   PubMed Web of Science ®Google Scholar
• Brody J. A., Chase T. N., Gordon E. K. Depressed monoamine catabolite levels in the cerebrospinal fluid of patients with Parkinsonism dementia of Guam. New England Journal of Medicine 1970; 282: 947–950
   PubMed Web of Science ®Google Scholar
• Carlsson A. Development of new pharmacological approaches in Parkinson's disease. Advances in Neurology, M. D. Yahr, K. J. Bergmann. Raven Press, New York 1986; Vol. 45: 513–518
   Google Scholar
• Chase T. N., Ng L. K. Y., August M. Parkinson's disease: Modification by 5-hydroxytryptophan. Neurology 1972; 22: 479–484
   PubMed Web of Science ®Google Scholar
• Curzon G. Brain amine metabolism in some neurological and psychiatric disorders. Biochemical aspects of nervous diseases, J. N. Cumings. Plenum Press, New York, London 1972; 151–212
   Google Scholar
• Fahn S., Snider S., Prasad A. L. Normalization of brain serotonin in levodopa treated rats by L-tryptophan. Neurology 1975; 25: 861–865
   PubMedGoogle Scholar
• Fahn S., Libsch L. R., Cutler R. W. Monoamines in the human neostriatum: Topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor. Journal of the Neurological Sciences 1971; 14: 427–455
   PubMed Web of Science ®Google Scholar
• Farber J., Miller J. D., Crawford K. A., McMillen B. A. Dopamine metabolism and receptor sensitivity in brian after REM sleep deprivation. Pharmacology Biochemistry and Behavior 1983; 18: 509–513
   PubMed Web of Science ®Google Scholar
• Fowler C. J. Antidepressant action and circadian rhythm changes. Trends in Neurosciences 1983; 4: 192
   Google Scholar
• Gerson S. C., Baldessarini R. J. Motor effects of serotonin in the central nervous system. Life Sciences 1980; 27: 1435–1451
   PubMed Web of Science ®Google Scholar
• Goldstein M., Frenkel R. Inhibition of serotonin by Dopa and other catechols. Nature (New Biology) 1971; 233: 179
   PubMedGoogle Scholar
• Gottfries C. G., Gottfries I., Roos B. E. Homovanillic-acid and 5-hydroxyindoleacetic acid in the cerebrospinal fluid of patients with senile dementia, presenile dementia and Parkinsonism. Journal of Neurochemistry 1969; 16: 1341–1345
   PubMed Web of Science ®Google Scholar
• Hornykiewicz O. Brain neurotransmitter changes in Parkinson's disease. Movement disorders, C. D. Marsden, S. Fahn. Butterworths, London 1982; 41–58
   Google Scholar
• Hornykiewicz O. Neurohumeral interactions and basal-ganglia function and dysfunction. The basla ganglia, M. D. Yahr. Raven Press, New York 1976; 269–280
   Google Scholar
• Hutt C. S., Snider S. R., Fahn S. Interaction between bromocriptine and levodopa. Neurology 1977; 27: 505–510
   Web of Science ®Google Scholar
• Jankovic J. Management of motor side-effects of chronic levodopa therapy. Clinical Neuropharmacology 1982; 5: S19–S28, (suppl)
   Web of Science ®Google Scholar
• Kienzl E., Rieder P., Jellinger K., Wesemann W. Transitional states of central serotonin receptors in Parkinson's disease. Journal of Neural Transmission 1981; 51: 113–122
   PubMed Web of Science ®Google Scholar
• Kizer J. S., Palkovits M., Brownstein M. J. The projections of the A8, A9, and A10 dopaminergic cell bodies: Evidence for a nigro-hypothalamic-median eminence dopaminergic pathwayt. Brain Research 1976; 108: 363–370
   PubMed Web of Science ®Google Scholar
• Kozell L., Sandyk R., Wagner G. C., Fisher H. The effects of L-tryptophan on halopheridol-induced movement disorder in the rat. Life Sciences 1987; 41: 1739–1744
   PubMed Web of Science ®Google Scholar
• Mayeux R., Stern Y., Cote L., Williams J. B. W. Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology 1984; 34: 642–646
   PubMed Web of Science ®Google Scholar
• Melamed E., Hefti F., Liebman J., Schlosbrg A. J., Wurtman R. J. Serotonergic neurones are not involved in action of L-dopa in Parkinson's disease. Nature 1980; 282: 772–774
   Google Scholar
• Nausieda P. A., Tanner C. M., Klawans H. L. Serotonergically active agents in levodopa-induced psychiatric toxicity reactions. Advances in neurology, S. Fahn, D. B. Calne, I. Shoulson. Raven Press, New York 1983; Vol. 37: 23–32
   Google Scholar
• Nausieda P. A., Weiner W. J., Kaplan L. R., Weber S., Klawans H. L. Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis. Clinical Neuropharmacology 1982; 5: 183–194
   PubMed Web of Science ®Google Scholar
• Ng K. Y., Chase T. N., Colburn R. W., Kopin I. J. L-dopa induced release of cerebral monoamines. Science 1970; 170: 76
   PubMed Web of Science ®Google Scholar
• Parkes J. D. Sleep and its disorders. W. B. Saunders Company, London 1985; 119–183
   Google Scholar
• Rabey J. M., Vardi J., Askenazi J. J., Streifler M. L-tryptophan administration in L-dopa-induced halluncinations in elderly Parkinsonian patients. Gerontology 1977; 23: 438–444
   PubMed Web of Science ®Google Scholar
• Sandyk R. L-dopa induced “Serotonin syndrome” in a Parkinsonian patient on bromocriptine. Journal of Clinical Pschopharmacology 1986; 6: 194–195
   PubMed Web of Science ®Google Scholar
• Sandyk R., Consroe P., Iacono R. P. L-tryptophan in drug-induced movement disorders with insomnia. New England Journal of Medicine 1986; 314: 1257
   PubMed Web of Science ®Google Scholar
• Sandyk R., Iacono R. P., Bamford C. R. Spinal cord mechanisms in amitriptyline responsive restless legs syndrome in Parkinson's disease. International Journal of Neurosciences 1988; 38: 121–124
   PubMed Web of Science ®Google Scholar
• Sano V. I., Taniguchi K. L-5-hydroxytroptophan (L-5-HTP)- Therapie des morbus Parkinson. Munschner Wochenschrift 1972; 114: 1717–1719
   PubMedGoogle Scholar
• Scatton B., Dennis T., L'Heureux R., Monfort J. C., Duyckaerts C., Javoy-Agid F. Degeneration of noradrenergic and serotonergic but not dopaminergic neurones in the lumbar spinal cord of Parkinsonian patients. Brain Research 1986; 380: 181–185
   PubMed Web of Science ®Google Scholar
• Scatton B., Javoy-Agid F., Rouquier L., Dubois B., Agid Y. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Research 1983; 275: 321–328
   PubMed Web of Science ®Google Scholar
• Strang R. R. The symptom of restless legs. Medical Journal of Australia 1967; 1: 1211–1216
   PubMedGoogle Scholar